Bedside to bench: interfering with leukemic stem cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Navigating the road toward optimal initial therapy for chronic myeloid leukemia.Current opinion in hematology · 2011
   Review
2. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Seminars in hematology · 2010
   Review
3. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.Leukemia · 2010
   Review
4. IFN-alpha wakes up sleeping hematopoietic stem cells.Nature medicine · 2009
   Article
5. Toward a cure for chronic myeloid leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as